{name}
{subtitle}
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~63 mi. (Pessade, France, +140 more cities)
facility
CHU Bordeaux Haut-Leveque ( Site 0185)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
city
~63 mi. (Pessade, France, +105 more cities)
facility
CHU Bordeaux Haut-Leveque ( Site 0457)
drug
bevacizumab, +1 more drug
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~63 mi. (Pessade, France, +201 more cities)
facility
CHU Bordeaux - Hopital Haut Lévêque /ID# 220989
drug
azacitidine, +1 more drug
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
city
~63 mi. (Pessade, France, +127 more cities)
facility
CHU Bordeaux - Hopital Haut Lévêque /ID# 214055
drug
azacitidine, +2 more drugs
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~63 mi. (Pessade, France, +197 more cities)
facility
CHU Bordeaux - Hopital Haut Lévêque /ID# 215150
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
~63 mi. (Pessade, France, +165 more cities)
facility
CHU Bordeaux - Hopital Haut Lévêque /ID# 222518
biomarker
del(11)(q10), +27 more biomarkers
drug
navitoclax, +1 more drug
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~82 mi. (Clermont-Ferrand, France, +226 more cities)
facility
Centre Jean Perrin ( Site 0434)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~82 mi. (Clermont-Ferrand, France, +207 more cities)
facility
Centre Jean Perrin ( Site 0909)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~82 mi. (Clermont-Ferrand, France, +159 more cities)
facility
Centre Jean Perrin ( Site 0460)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~82 mi. (Clermont-Ferrand, France, +137 more cities)
facility
CHU Estaing ( Site 0360)